Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Aldape

Showing results (311-320 of 345) with videos related to

Pageof 35
Sort By:
Cell Reports Methods|April 27, 2022
MPA<sub>PASS</sub> software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assaysJoshua A Welsh, Bryce Killingsworth, Julia Kepley, et al.
The Journal of Clinical Investigation|October 26, 2018
DNA hypermethylation within TERT promoter upregulates TERT expression in cancerDonghyun D Lee, Ricardo Leão, Martin Komosa, et al.
Neuro-Oncology|November 6, 2024
Validation and next-generation update of a DNA methylation-based recurrence predictor for meningioma: A multicenter prospective studyAlexander P Landry, Justin Z Wang, Vikas Patil, et al.
Neuro-Oncology|May 19, 2026
Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade GliomaChelsea Kotch, Sebastien Perreault, Phoebe Power, et al.
Journal of the National Cancer Institute|December 9, 2014
Germline mutations in shelterin complex genes are associated with familial gliomaMatthew N Bainbridge, Georgina N Armstrong, M Monica Gramatges, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2022
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON TrialC Mircea S Tesileanu, Marc Sanson, Wolfgang Wick, et al.
Nature Medicine|July 21, 2025
Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trialFarshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
Nature Medicine|May 15, 2023
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trialFarshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
The Lancet. Oncology|May 17, 2021
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 studyMartin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, et al.
Biorxiv : the Preprint Server for Biology|August 1, 2025
Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathologySumit Mukherjee, Sumeet Patiyal, Lipika R Pal, et al.
Pageof 35

Showing results (311-320 of 345) with videos related to

Sort By:
Pageof 35
Cell Reports Methods|April 27, 2022
MPA<sub>PASS</sub> software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assaysJoshua A Welsh, Bryce Killingsworth, Julia Kepley, et al.
The Journal of Clinical Investigation|October 26, 2018
DNA hypermethylation within TERT promoter upregulates TERT expression in cancerDonghyun D Lee, Ricardo Leão, Martin Komosa, et al.
Neuro-Oncology|November 6, 2024
Validation and next-generation update of a DNA methylation-based recurrence predictor for meningioma: A multicenter prospective studyAlexander P Landry, Justin Z Wang, Vikas Patil, et al.
Neuro-Oncology|May 19, 2026
Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade GliomaChelsea Kotch, Sebastien Perreault, Phoebe Power, et al.
Journal of the National Cancer Institute|December 9, 2014
Germline mutations in shelterin complex genes are associated with familial gliomaMatthew N Bainbridge, Georgina N Armstrong, M Monica Gramatges, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2022
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON TrialC Mircea S Tesileanu, Marc Sanson, Wolfgang Wick, et al.
Nature Medicine|July 21, 2025
Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trialFarshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
Nature Medicine|May 15, 2023
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trialFarshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
The Lancet. Oncology|May 17, 2021
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 studyMartin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, et al.
Biorxiv : the Preprint Server for Biology|August 1, 2025
Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathologySumit Mukherjee, Sumeet Patiyal, Lipika R Pal, et al.
Pageof 35